AlphAIalphai — Financial news for AI agents
marketscreener.comAUG 311 min read

Morgan Stanley Initiates Coverage on Attovia Therapeutics With Overweight Rating

Morgan Stanley initiated coverage on Attovia Therapeutics with an Overweight rating. Leerink Partners also started coverage with an Outperform rating and a $52 price target. The stock has seen a 5-day change of 20.70 USD, a 1st Jan change of -3.54%, and a year-to-date change of -0.48%.

Original reporting
marketscreener.com
Published Aug 31, 2026, 11:18 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 12:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ATTO
Relevance
7/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

Analyst coverage can act as a catalyst for price movement.

02

Market read

New coverage may prompt short-term buying pressure.

03

What to watch

Potential dilution from future financing rounds.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Attovia Therapeutics is a clinical-stage biotech focused on rare diseases.

Market effects

Sector

May boost sentiment for biotech sector peers.

Regional

Limited to US biotech investors.

Global

Minor, confined to niche biotech investors.

Counterpoint

What could challenge this read

Rating could be premature if upcoming trial data disappoints.

Key entities

  • Analyst
    Morgan Stanley

    Initiated coverage with overweight rating.

Read at source← All news

Related articles

SEP 2
$ATTOMedAI 8/10

Attovia Therapeutics, Inc. (ATTO): Results of Operations and Financial Condition

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of

SEC EDGAR 8-K2 min
AUG 31
$ATTOMedAI 8/10

Wall Street analysts bullish on Attovia as itch drug data fuel biotech optimism

Attovia Therapeutics received bullish ratings from Citi, Morgan Stanley, and RBC, with price targets ranging from $30 to $45, citing promising early data for its chronic-itch drug ATTO-1310 and its antibody platform. The stock, trading around $21, has significant upside potential according to analysts. The company has $420M in cash post-IPO, reducing near-term financing concerns. Analysts caution about clinical-stage risks, including trial outcomes and competition.

investing.com2 min
AUG 7
$ATTOMedAI 8/10

Attovia raises $265m in upsized IPO for trials

Attovia filed an amended S-1 for an upsized IPO raising about $265.1 million in net proceeds, up from roughly $182.4 million earlier. Funds will support two Phase II trials starting in H1 2027 for ATTO-1310, an engineered biologic targeting IL-31 for chronic pruritic diseases. The filing cites Phase Ib results and prior funding rounds.

bioxconomy.com4 min
AUG 5
$ATTOMedAI 8/10

Attovia Therapeutics prices IPO at $17 per share on Nasdaq

Attovia Therapeutics (Nasdaq: ATTO) priced its IPO at $17.00 per share, selling 17.0 million shares for expected gross proceeds of about $289.0 million, with a 30-day option for up to 2.55 million more shares. The stock is set to start trading Aug. 5, 2026, under ATTO. Joint bookrunners include Morgan Stanley, Leerink, Citigroup, and RBC.

investing.com3 min